|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma:a propensity score matching analysis显示文摘Background:A growing body of evidence supports the use of laparoscopic pancreaticoduodenectomy(LPD)as an efficient and feasible surgical technique.However,few studies have investigated its applicability in pancreatic ductal adenocarcinoma(PDAC),and the long-term efficacy of LPD on PDAC remains unclear.This study aimed to compare the short-and long-term outcomes between LPD and open pancreaticoduodenectomy(OPD)for PDAC.Methods:The data of patients who had OPD or LPD for PDAC between January 2013 and September 2017 were retrieved.Their postoperative outcomes and survival were compared after propensity score matching.Results:A total of 309 patients were included.After a 2:1 matching,93 cases in the OPD group and 55 in the LPD group were identified.Delayed gastric emptying(DGE),particularly grade B/C DGE,occurred less frequently in the LPD group than in the OPD group(1.8%vs.36.6%,P<0.001;1.8%vs.22.6%,P=0.001).The overall complication rates were significantly lower in the LPD group than in the OPD group(49.1%vs.71.0%,P=0.008),whereas the rates of major complications were similar(10.9%vs.14.0%,P=0.590).In addition,the median overall survival was comparable between the two groups(20.0 vs.18.7 months,P=0.293).Conclusion:LPD was found to be technically feasible with efficacy similar to OPD for patients with PDAC. | Wentao Zhou Weiwei Jin Dansong Wang Chao Lu Xuefeng Xu Renchao Zhang Tiantao Kuang Yucheng Zhou Wenchuan Wu Dayong Jin Yiping Mou Wenhui Lou | 2019 | Cancer Communications2019，39，1： | 14 |
| 2 | Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells显示文摘 | Yefei Rong Wenchuan Wu Xiaoling Ni Tiantao Kuang Dayong Jin Dansong Wang Wenhui Lou | 2013 | Tumor Biology2013，，： | 1 |
| 3 | Efficacy and safety of S-1 based adjuvant chemoradiotherapy for resected pancreatic ductal adenocarcinoma with high-risk pathological feature: a prospective, single-arm, interventional study显示文摘Objective: It remains unclear whether adjuvant chemoradiotherapy (CRT) improves survival outcome of pancreatic ductal adenocarcinoma (PDAC) patients after surgery. This study aimed to investigate the efficacy and safety of tegafur/gimeracil/oteracil (S-1)-based adjuvant concurrent chemoradiotherapy in resected PDAC patients with defined high-risk pathological features.Methods: We conducted a single-arm, prospective, and interventional study at Zhongshan Hospital Fudan University from December 2012 to December 2019 and the last follow-up was conducted in December 2021. This study was approved by the Ethics Committee of Zhongshan Hospital Fudan University on December 27, 2012 (approval No. B2012-139). Resected PDAC patients with high-risk pathological features, including positive resection margin, pathological T3-4N1-2M0 disease, peripancreatic fat invasion, microvascular invasion, and perineural invasion, were recruited. Primary endpoint was overall survival and secondary endpoints were disease-free survival, treatment toxicity, and 2-, 5-year survival rates.Results: A total of 54 patients were recruited. Mean age was 63.6 years old (±7.2). The distribution of T and N stages were 24.1% for T1, 46.3% for T2, 27.8% for T3, 1.9% for T4, 33.3% for N1, and 11.1% for N2. Seven patients had R1 resection. The median overall survival and disease-free survival were 27.1 and 13.7 months, respectively, while no fatal adverse events were recorded. Subgroup analyses showed differences in survival outcomes among patients with microvascular invasion, different N stages, and preoperative CA 19-9 levels. Further, a Cox proportional hazard model demonstrated associations of lymph node metastases, CA 19-9 level, and microvascular invasion with overall survival and disease-free survival.Conclusion: S-1 -based adjuvant CRT showed promising efficacy and manageable toxicity in resected PDAC patients with highrisk pathological features. | Lili Wu Yaolin Xu Zhaochong Zeng Yixing Chen Yuhong Zhou Dansong Wang Jing Sun Minzhi Lv Shisuo Du Wenhui Lou | 2022 | Journal of Pancreatology2022，5，1： | 1 |
| 4 | Targeted deep sequencing reveals the genetic heterogeneity in well-differentiated pancreatic neuroendocrine tumors with liver metastasis显示文摘Background:Pancreatic neuroendocrine tumor is a rare and heterogeneous entity,and approximately half of the patients harbored liver metastasis when initially diagnosed,whose prognosis is dismal.High-throughput sequencing has largely uncovered the genomic features of pancreatic neuroendocrine tumor,but the genetic alterations in the metastatic cases remain relatively unclear,which we aimed to study.Methods:Pathologically confirmed well-differentiated pancreatic neuroendocrine tumor samples resected in our hospital from 2000 to 2019 were collected.We performed deep sequencing on the exome of 341 tumor-related genes,and compared the differences of genetic alterations between the metastatic and the non-metastatic cases,as well as between the primary and the paired liver metastatic tumors.Results:Sequencing data of 79 samples from 29 pancreatic neuroendocrine tumor patients were included into analysis.A total of 2,471 somatic variants were identified,75.5%of which were considered as low-abundance.NOTCH1 was the most frequently mutated gene,altered in 26(53.1%)pancreatic neuroendocrine tumor samples from 18(62.1%)patients.Compared with the non-metastatic pancreatic neuroendocrine tumors,the metastatic cases were discovered with more single nucleotide variants and copy number variations,indicating the increased genomic instability.In addition,among the paired metastatic cases,the primary and the metastatic lesions shared limited mutated genes.Conclusions:Through the targeted deep sequencing,we identified the intratumor,intraindividual,and interindividual heterogeneity in the pancreatic neuroendocrine tumor patients,particularly in the metastatic cases,bringing potential challenges for the current biopsy strategies in guiding clinical treatments. | Wentao Zhou Xu Han Yuan Ji Dansong Wang Dong Xie Zilong Qiu Wenhui Lou | 2023 | Hepatobiliary Surgery and Nutrition2023，12，3： | 0 |
| 5 | An analysis of clinico-pathologic features of intraductal papillary mucinous neoplasm of the pancreas显示文摘The natural history and clinical manifestation of resected intraductal papillary mucinous neoplasm(IPMN)of the pancreas were elucidated,and based on this,a retrospective pancreatic database was reviewed to identify patients with IPMN who were surgically managed in our department from 1999 to June 2006.Pathologic rereview of each case was performed,and the clinico-pathologic features were examined.Student’s T test and x2 analysis were used to identify factors associated with malignancy.Fifty-one patients were identified.There were 33 males and 18 females.One patient’s pancreas was unresectable,two patients underwent a total pancreatectomy,42 patients had a pancreatecoduodenectomy and five patients had distal pancreatectomy.Main-duct type carcinoma was identified in 24 patients;branch-duct type in 15 patients,and mixed type in 12 patients.Invasive carcinoma was present in 35 patients.Weight loss and jaundice occurred more commonly in the invasive group.The average serum CA19-9 level was significantly higher in the invasive group(1542μ vs 94.5μ).The average diameter of the pancreatic duct was also wider in the invasive group(8.7 mm vs 4.3 mm).Significant predictors of malignant IPMNs included weight loss,jaundice,a high level of serum CA19-9,a large pancreatic duct and main-duct type carcinoma. | LOU Wenhui JIN Dayong WANG Dansong XU Xuefeng KUANG Tiantao QIN Xinyu | 2007 | Frontiers of Medicine2007，1，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员